A vesicle containing a saccharide isomerate, a hydrolyzed lupine protein, and an intercorneocyte lipid mimetics as an active ingredient, the vesicle comprising: an oil phase part obtained by dispersing 10 wt% to 75 wt% of the intercorneocyte lipid mimetics and 1 wt% to 15 wt% of lysolecithin in 1 wt% to 25 wt% of glycerin based on the total weight of the vesicle; and an aqueous phase part obtained by dissolving 0.01 wt% to 7 wt% of the saccharide isomerate and 0.01 wt% to 7 wt% of the hydrolyzed lupine protein in the balance of purified water based on the total weight of the vesicle; wherein the intercorneocyte lipid mimetics includes 10 wt% to 70 wt% of an intercorneocyte lipid component, 0.1 wt% to 20 wt% of a surfactant, 2 wt% to 20 wt% of saturated lecithin, 5 wt% to 20 wt% of glycerin, and the balance of purified water based on a total weight of the intercorneocyte lipid mimetics; wherein the intercorneocyte lipid component includes 5 wt% to 60 wt% of ceramide, 5 wt% to 35 wt% of a cholesterol derivative containing cholesterol or a phytosterol derivative containing phytosterol, and 5 wt% to 60 wt% of a higher fatty acid based on a total weight of the intercorneocyte lipid component; wherein the cholesterol derivative is selected from at least one of cholesteryl macadamiate and cholesteryl lanolate; wherein the phytosterol derivative is selected from at least one of phytosterol macadamia nut fatty acid ester, phytosteryl rice branate, phytosteryl macadamiate, phytosteryl oleate, phytosteryl isostearate, phytosteryl canola glyceride, and phytosteryl hydroxystearate; wherein the higher fatty acid is a mixture of a palmitic acid, a stearic acid, an oleic acid, and a linolenic acid; and wherein the surfactant is selected from the group consisting of glyceryl lanolate, glyceryl linolenate, glyceryl linoleate, glyceryl ricinoleate, glyceryl myristate, glyceryl behenate, glyceryl stearate, glyceryl stearate citrate, glyceryl olivate, glyceryl oleate, glyceryl undecylenate, glyceryl isostearate, glyceryl cocoate, and glyceryl palmitate. an oil phase part obtained by dispersing 10 wt% to 75 wt% of the intercorneocyte lipid mimetics and 1 wt% to 15 wt% of lysolecithin in 1 wt% to 25 wt% of glycerin based on the total weight of the vesicle; and an aqueous phase part obtained by dissolving 0.01 wt% to 7 wt% of the saccharide isomerate and 0.01 wt% to 7 wt% of the hydrolyzed lupine protein in the balance of purified water based on the total weight of the vesicle; wherein the intercorneocyte lipid mimetics includes 10 wt% to 70 wt% of an intercorneocyte lipid component, 0.1 wt% to 20 wt% of a surfactant, 2 wt% to 20 wt% of saturated lecithin, 5 wt% to 20 wt% of glycerin, and the balance of purified water based on a total weight of the intercorneocyte lipid mimetics; wherein the intercorneocyte lipid component includes 5 wt% to 60 wt% of ceramide, 5 wt% to 35 wt% of a cholesterol derivative containing cholesterol or a phytosterol derivative containing phytosterol, and 5 wt% to 60 wt% of a higher fatty acid based on a total weight of the intercorneocyte lipid component; wherein the cholesterol derivative is selected from at least one of cholesteryl macadamiate and cholesteryl lanolate; wherein the phytosterol derivative is selected from at least one of phytosterol macadamia nut fatty acid ester, phytosteryl rice branate, phytosteryl macadamiate, phytosteryl oleate, phytosteryl isostearate, phytosteryl canola glyceride, and phytosteryl hydroxystearate; wherein the higher fatty acid is a mixture of a palmitic acid, a stearic acid, an oleic acid, and a linolenic acid; and wherein the surfactant is selected from the group consisting of glyceryl lanolate, glyceryl linolenate, glyceryl linoleate, glyceryl ricinoleate, glyceryl myristate, glyceryl behenate, glyceryl stearate, glyceryl stearate citrate, glyceryl olivate, glyceryl oleate, glyceryl undecylenate, glyceryl isostearate, glyceryl cocoate, and glyceryl palmitate. <EOS>